Lake Street Capital Markets initiates coverage on P3 Health Partners stock with Buy rating

Published 28/08/2025, 14:34
Lake Street Capital Markets initiates coverage on P3 Health Partners stock with Buy rating

Investing.com - Lake Street Capital Markets initiated coverage on P3 Health Partners Inc (NASDAQ:PIII) with a Buy rating and a price target of $20.00 on Thursday. According to InvestingPro data, the company currently trades at $7.85, with a market capitalization of $58.22 million.

The research firm cited P3’s development of a physician-led, patient-centric care model for delivering value-based care as a key factor in its positive outlook.

Lake Street Capital Markets expressed confidence that value-based care will increasingly represent a greater proportion of healthcare delivery, positioning P3 to benefit from this industry trend.

The firm noted that P3’s business model is capital-light and the company has previously demonstrated its ability to ramp up at-risk membership, despite experiencing challenges since its SPAC public offering.

Lake Street Capital Markets also highlighted that P3 has installed a new management team and possesses an experienced board, suggesting that if the company proves it can operate profitably, investors may assign PIII shares a higher multiple. InvestingPro subscribers can access detailed financial health scores and additional ProTips to better evaluate the company’s turnaround potential.

In other recent news, P3 Health Partners announced its Q2 2025 earnings, reporting a revenue of $356 million, which exceeded the forecast of $349.73 million. This revenue achievement highlights the company’s strong financial performance in the quarter. Despite the positive revenue results, the stock’s recent movement suggests investors may have concerns about broader financial health, though this is not directly tied to the earnings report. The earnings call did not provide further insights into potential future developments or strategies. No recent mergers or acquisitions were reported by P3 Health Partners. Additionally, there have been no recent analyst upgrades or downgrades affecting the company. These developments are part of the ongoing updates investors are monitoring.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.